Among patients with other myeloid haematological neoplasms, SRSF2 mutations are particularly frequent (28–30%) among CMML cases [150] and, to a less extent, MDS (11%) and AML (6%) patients [124,134,150]. This evidence concerns the gene SRSF2 and chronic myelomonocytic leukemia.